Xillix Technologies Corp.
TSX : XLX

Xillix Technologies Corp.

July 11, 2005 14:37 ET

Xillix Receives U.S. Patent for Fluorescence Endoscopy Innovation

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - July 11, 2005) - Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy for the early detection of cancer, today announced that the U.S. Patent Office has granted to Xillix patent number 6,899,675B2 entitled "Fluorescence Endoscopy Video Systems with No Moving Parts in the Camera." This patent covers the implementation details of a new camera for fluorescence endoscopy and is one of several next-generation technologies being investigated as a follow-up to the current Onco-LIFE™ product. Specifically, this patent describes a compact camera for white light and fluorescence imaging, which contains no moving parts and may be located in the insertion portion of an endoscope.

"This patent is an example of Xillix's ongoing commitment to innovation and technological leadership," said John Fengler, VP Engineering & Development. "Approval of this patent further strengthens Xillix's solid IP position and demonstrates our commitment to developing a pipeline of market-leading products."

Xillix currently holds 11 U.S. and 32 international patents in fluorescence endoscopy technologies. The Company also has 6 U.S. and 35 international patents pending.

About Xillix

Xillix Technologies Corp. is a Canadian medical device company and the world leader in fluorescence endoscopy for improved cancer detection. Xillix's latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. An international multicenter lung cancer clinical trial of Onco-LIFE demonstrated a 325% per-lesion improvement in the detection of early lung cancer (moderate-severe dysplasia and carcinoma in situ) and a 250% per-patient improvement compared to white-light alone. Onco-LIFE is approved for sale in the United States for the lung application and in Europe and Canada for both lung and GI applications. Onco-LIFE is compact, user-friendly and is compatible with a wide range of endoscopes and endoscopic accessories to help maximize global market acceptance

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated March 31, 2005.

The Company is listed on the Toronto Stock Exchange under the trading symbol "XLX".

Contact Information